GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Senzime AB (OSTO:SEZI) » Definitions » EV-to-Revenue

Senzime AB (OSTO:SEZI) EV-to-Revenue : 17.93 (As of Jun. 09, 2024)


View and export this data going back to 2008. Start your Free Trial

What is Senzime AB EV-to-Revenue?

EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Senzime AB's enterprise value is kr727.52 Mil. Senzime AB's Revenue for the trailing twelve months (TTM) ended in Mar. 2024 was kr40.59 Mil. Therefore, Senzime AB's EV-to-Revenue for today is 17.93.

The historical rank and industry rank for Senzime AB's EV-to-Revenue or its related term are showing as below:

OSTO:SEZI' s EV-to-Revenue Range Over the Past 10 Years
Min: 8.28   Med: 132.84   Max: 2019.8
Current: 17.93

During the past 13 years, the highest EV-to-Revenue of Senzime AB was 2019.80. The lowest was 8.28. And the median was 132.84.

OSTO:SEZI's EV-to-Revenue is ranked worse than
88.62% of 826 companies
in the Medical Devices & Instruments industry
Industry Median: 3.065 vs OSTO:SEZI: 17.93

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

As of today (2024-06-09), Senzime AB's stock price is kr6.96. Senzime AB's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2024 was kr0.39. Therefore, Senzime AB's PS Ratio for today is 17.76.


Senzime AB EV-to-Revenue Historical Data

The historical data trend for Senzime AB's EV-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Senzime AB EV-to-Revenue Chart

Senzime AB Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 137.69 143.72 123.10 52.56 20.97

Senzime AB Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
EV-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 22.45 9.10 21.49 20.97 15.68

Competitive Comparison of Senzime AB's EV-to-Revenue

For the Medical Devices subindustry, Senzime AB's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Senzime AB's EV-to-Revenue Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Senzime AB's EV-to-Revenue distribution charts can be found below:

* The bar in red indicates where Senzime AB's EV-to-Revenue falls into.



Senzime AB EV-to-Revenue Calculation

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

Senzime AB's EV-to-Revenue for today is calculated as:

EV-to-Revenue=Enterprise Value (Today)/Revenue (TTM)
=727.517/40.586
=17.93

Senzime AB's current Enterprise Value is kr727.52 Mil.
Senzime AB's Revenue for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was kr40.59 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Senzime AB  (OSTO:SEZI) EV-to-Revenue Explanation

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

Senzime AB's PS Ratiofor today is calculated as:

PS Ratio=Share Price (Today)/Revenue per Share (TTM)
=6.96/0.392
=17.76

Senzime AB's share price for today is kr6.96.
Senzime AB's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was kr0.39.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Senzime AB EV-to-Revenue Related Terms

Thank you for viewing the detailed overview of Senzime AB's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Senzime AB (OSTO:SEZI) Business Description

Traded in Other Exchanges
Address
Ulls vag 41, Uppsala, SWE, 756 51
Senzime AB, a medical technology company, develops, manufactures, and markets patient monitoring systems for monitoring patients. Its solutions are designed to ensure maximum patient benefit, reduce complications associated with surgery and anesthesia, and decrease healthcare costs. Its product includes TetraGraph and TetraSens, ExSpiron, TetraSens Pediatric, and TetraConnect. Its geographical segments include Sweden, the United States, Europe/Oceania, and Asia.

Senzime AB (OSTO:SEZI) Headlines

No Headlines